Belgira, Baby Girl .
HRN: 26-14-34 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/27/2024
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
11/26/2024
12/03/2024
IV
33mg
Q 24
PSNB
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes